Preferred Label : Lacosamide;
MeSH definition : An acetamide derivative that acts as a blocker of VOLTAGE-GATED SODIUM CHANNELS. It
is used as an anticonvulsant, for adjunctive or monotherapy, in the treatment of PARTIAL
SEIZURES.;
Related MeSH term : N benzyl 2 acetamido 3 methoxypropionamide; N-benzyl-AcMeOPrNH2; N benzyl AcMeOPrNH2;
MeSH CAS label : Propanamide, 2-(acetylamino)-3-methoxy-N-(phenylmethyl)-, (2R)-;
UNII : 563KS2PQY5;
Origin ID : D000078334;
UMLS CUI : C0893761;
ATC code(s)
ATC code(s)
Allowable qualifiers
Pharmacological action(s)
Record concept(s)
Semantic type(s)
Validated automatic mappings to BTNT
An acetamide derivative that acts as a blocker of VOLTAGE-GATED SODIUM CHANNELS. It
is used as an anticonvulsant, for adjunctive or monotherapy, in the treatment of PARTIAL
SEIZURES.
https://www.ema.europa.eu/en/medicines/human/EPAR/lacosamide-adroiq
2023
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
Lacosamide
Lacosamide
lacosamide
drugs, generic
epilepsies, partial
adult
adolescent
child
primary generalized tonic-clonic seizures
drug therapy, combination
epilepsy, generalized
epilepsy, idiopathic generalized
infusions, intravenous
anticonvulsants
anticonvulsants
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
---
https://www.has-sante.fr/jcms/p_3264975/fr/vimpat-lacosamide
2021
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
insurance, health, reimbursement
primary generalized tonic-clonic seizures
epilepsy, tonic-clonic
adult
adolescent
child
Lacosamide
anticonvulsants
lacosamide
---
https://www.cochrane.org/fr/CD008841/EPILEPSY_le-lacosamide-en-traitement-adjuvant-dans-lepilepsie-focale
2021
France
United Kingdom
review of literature
french abstract
Epilepsy
Epilepsy
adjuvant, nos
epilepsy
Lacosamide
epilepsies, partial
localization-related epilepsy, nos
epilepsy
---
https://www.ema.europa.eu/en/medicines/human/EPAR/lacosamide-ucb
2019
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug approval
europe
lacosamide
Lacosamide
Lacosamide
administration, oral
anticonvulsants
anticonvulsants
epilepsy
adult
adolescent
child
aged
drug interactions
pregnancy
breast feeding
Voltage-Gated sodium channel blockers
Voltage-Gated sodium channel blockers
drug evaluation, preclinical
---
https://www.has-sante.fr/portail/jcms/c_2885813/fr/vimpat
2018
false
false
false
France
child
epilepsies, partial
lacosamide
treatment outcome
insurance, health, reimbursement
anticonvulsants
evaluation of the transparency committee
vimpat
acetamides
acetamides
Lacosamide
Lacosamide
---
https://www.ema.europa.eu/medicines/human/EPAR/lacosamide-accord
2017
false
United Kingdom
French
English
syndication feed
drugs, generic
Product containing precisely lacosamide 50 milligram/1 each conventional release oral
tablet (clinical drug)
Product containing precisely lacosamide 100 milligram/1 each conventional release
oral tablet (clinical drug)
Product containing precisely lacosamide 150 milligram/1 each conventional release
oral tablet (clinical drug)
Product containing precisely lacosamide 200 milligram/1 each conventional release
oral tablet (clinical drug)
tablets
infusions, intravenous
treatment outcome
drug approval
acetamides
drug therapy, combination
acetamides
epilepsies, partial
adult
adolescent
administration, oral
anticonvulsants
anticonvulsants
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
lacosamide
package leaflet
summary of product characteristics
drug evaluation
Lacosamide
Lacosamide
---
http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=65347326
2014
false
false
false
France
French
summary of product characteristics
package leaflet
lacosamide
2-(acetylamino)-3-methoxy-N-(phenylmethyl)-, (2R)-
pharmaceutical solutions
amides
propane
acetamides
Lacosamide
---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=61955936
2012
France
summary of product characteristics
package leaflet
2-(acetylamino)-3-methoxy-N-(phenylmethyl)-, (2R)-
tablets
Lacosamide
---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=62377079
2012
France
summary of product characteristics
package leaflet
2-(acetylamino)-3-methoxy-N-(phenylmethyl)-, (2R)-
tablets
Lacosamide
---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=62359608
2012
France
summary of product characteristics
package leaflet
tablets
2-(acetylamino)-3-methoxy-N-(phenylmethyl)-, (2R)-
Lacosamide
---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=62229123
2012
France
summary of product characteristics
package leaflet
tablets
2-(acetylamino)-3-methoxy-N-(phenylmethyl)-, (2R)-
Lacosamide
---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=65484410
2012
France
summary of product characteristics
package leaflet
2-(acetylamino)-3-methoxy-N-(phenylmethyl)-, (2R)-
pharmaceutical solutions
Lacosamide
---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=64967356
2012
France
summary of product characteristics
package leaflet
2-(acetylamino)-3-methoxy-N-(phenylmethyl)-, (2R)-
Lacosamide
---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=64357958
2012
France
summary of product characteristics
package leaflet
tablets
2-(acetylamino)-3-methoxy-N-(phenylmethyl)-, (2R)-
Lacosamide
---
https://www.inesss.qc.ca/thematiques/medicaments/medicaments-evaluation-aux-fins-dinscription/extrait-davis-au-ministre/vimpat-1627.html
2012
false
Canada
French
English
evaluation of the transparency committee
acetamides
infusions, intravenous
clinical trials as topic
lacosamide
anticonvulsants
treatment outcome
Cost-Benefit analysis
epilepsies, partial
drug evaluation
Lacosamide
---
https://www.ema.europa.eu/medicines/human/EPAR/Vimpat
2012
false
United Kingdom
French
English
syndication feed
treatment outcome
drug approval
drug labeling
acetamides
drug therapy, combination
acetamides
epilepsies, partial
adult
adolescent
administration, oral
infusions, intravenous
anticonvulsants
anticonvulsants
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
lacosamide
package leaflet
summary of product characteristics
drug evaluation
Lacosamide
Lacosamide
---
Summary Basis of Decision (SBD) VIMPAT - Lacosamide, 50 mg, 100 mg, 150 mg and 200
mg tablets; 10 mg/mL solution for injection
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailOne.php?lang=fr&linkID=SBD00305
2011
false
Canada
English
French
acetamides
acetamides
administration, oral
treatment outcome
risk assessment
drug approval
infusions, intravenous
anticonvulsants
anticonvulsants
adult
lacosamide
epilepsies, partial
randomized controlled trials as topic
multicenter studies as topic
drug evaluation
Lacosamide
Lacosamide
---
http://www.has-sante.fr/portail/jcms/c_813835/vimpat-lacosamide-antiepileptique
http://www.has-sante.fr/portail/jcms/c_765733/vimpat-ct-6048
2009
France
French
anticonvulsants
epilepsy
acetamides
lacosamide
acetamides
guidelines for drug use
evaluation of the transparency committee
Lacosamide
---
https://www.has-sante.fr/portail/jcms/c_2818028/fr/vimpat
https://www.has-sante.fr/portail/jcms/c_2818028/fr/vimpat-lacosamide-antiepileptique
2009
false
France
French
epilepsies, partial
administration, oral
infusions, intravenous
adolescent
adult
treatment outcome
insurance, health, reimbursement
child
anticonvulsants
acetamides
lacosamide
guidelines for drug use
evaluation of the transparency committee
Lacosamide
---